E
Adverum Biotechnologies, Inc.
ADVM
$3.83
-$0.11-2.79%
E
Sell
3/12/2025Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 3/12/2025 due to a decline in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 3/12/2025 due to a decline in the volatility index.
D
Sell
2/19/2025Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 2/19/2025 due to an increase in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 2/19/2025 due to an increase in the volatility index.
E
Sell
2/3/2025Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 2/3/2025 due to a decline in the volatility index and total return index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 2/3/2025 due to a decline in the volatility index and total return index.
D
Sell
1/15/2025Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 1/15/2025 due to an increase in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 1/15/2025 due to an increase in the volatility index.
E
Sell
12/31/2024Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 12/31/2024 due to a decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.8861 to -$1.2998, EBIT declined 39.93% from -$20.88M to -$29.22M, and the quick ratio declined from 7.74 to 5.54.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 12/31/2024 due to a decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.8861 to -$1.2998, EBIT declined 39.93% from -$20.88M to -$29.22M, and the quick ratio declined from 7.74 to 5.54.
D
Sell
7/15/2024Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 7/15/2024 due to an increase in the volatility index and total return index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 7/15/2024 due to an increase in the volatility index and total return index.
E
Sell
6/28/2024Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 6/28/2024 due to a large decline in the total return index and volatility index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 6/28/2024 due to a large decline in the total return index and volatility index.
D
Sell
6/13/2024Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 6/13/2024 due to an increase in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 6/13/2024 due to an increase in the volatility index.
E
Sell
5/28/2024Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 5/28/2024 due to a decline in the volatility index, growth index and total return index. Operating cash flow declined 8.99% from -$21.33M to -$23.25M, and EBIT declined 3.49% from -$25.93M to -$26.84M.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 5/28/2024 due to a decline in the volatility index, growth index and total return index. Operating cash flow declined 8.99% from -$21.33M to -$23.25M, and EBIT declined 3.49% from -$25.93M to -$26.84M.
D
Sell
5/24/2024Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 5/24/2024 due to an increase in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 5/24/2024 due to an increase in the volatility index.
E
Sell
5/7/2024Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 5/7/2024 due to a decline in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 5/7/2024 due to a decline in the volatility index.
D
Sell
4/19/2024Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 4/19/2024 due to an increase in the total return index, volatility index and solvency index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 4/19/2024 due to an increase in the total return index, volatility index and solvency index.
E
Sell
4/4/2024Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 4/4/2024 due to a decline in the volatility index and solvency index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 4/4/2024 due to a decline in the volatility index and solvency index.
D
Sell
3/19/2024Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 3/19/2024 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.3256 to -$0.2343, EBIT increased 24.89% from -$34.53M to -$25.93M, and operating cash flow increased 10.81% from -$23.91M to -$21.33M.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 3/19/2024 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.3256 to -$0.2343, EBIT increased 24.89% from -$34.53M to -$25.93M, and operating cash flow increased 10.81% from -$23.91M to -$21.33M.
E
Sell
3/8/2024Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 3/8/2024 due to a decline in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 3/8/2024 due to a decline in the volatility index.
D
Sell
2/22/2024Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 2/22/2024 due to an increase in the volatility index and total return index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 2/22/2024 due to an increase in the volatility index and total return index.
E
Sell
2/6/2024Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 2/6/2024 due to a decline in the volatility index and growth index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 2/6/2024 due to a decline in the volatility index and growth index.
D
Sell
1/22/2024Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 1/22/2024 due to an increase in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 1/22/2024 due to an increase in the volatility index.
E
Sell
1/4/2024Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 1/4/2024 due to a decline in the volatility index and total return index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 1/4/2024 due to a decline in the volatility index and total return index.
D
Sell
12/20/2023Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 12/20/2023 due to an increase in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 12/20/2023 due to an increase in the volatility index.
E
Sell
11/30/2023Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 11/30/2023 due to a decline in the volatility index and total return index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 11/30/2023 due to a decline in the volatility index and total return index.
D
Sell
11/14/2023Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 11/14/2023 due to an increase in the growth index and volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 11/14/2023 due to an increase in the growth index and volatility index.
E
Sell
11/8/2023Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 11/8/2023 due to a decline in the growth index, volatility index and solvency index. Debt to equity increased from 0.17 to 0.19, the quick ratio declined from 3.54 to 3.18, and EBIT declined 9.35% from -$30.24M to -$33.07M.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 11/8/2023 due to a decline in the growth index, volatility index and solvency index. Debt to equity increased from 0.17 to 0.19, the quick ratio declined from 3.54 to 3.18, and EBIT declined 9.35% from -$30.24M to -$33.07M.
D
Sell
6/30/2023Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 6/30/2023 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.3276 to -$0.2897, and EBIT increased 10.57% from -$33.81M to -$30.24M.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 6/30/2023 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.3276 to -$0.2897, and EBIT increased 10.57% from -$33.81M to -$30.24M.
E
Sell
3/14/2023Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 03/14/2023.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 02/23/2023.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
11/14/2022Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 11/14/2022 due to a noticeable increase in the growth index and valuation index. EBIT increased 13.35% from -$42.01M to -$36.41M, and earnings per share increased from -$0.442 to -$0.4034.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 11/14/2022 due to a noticeable increase in the growth index and valuation index. EBIT increased 13.35% from -$42.01M to -$36.41M, and earnings per share increased from -$0.442 to -$0.4034.
E
Sell
10/10/2022Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 10/10/2022 due to a decline in the volatility index and total return index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 10/10/2022 due to a decline in the volatility index and total return index.
D
Sell
9/23/2022Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 9/23/2022 due to an increase in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 9/23/2022 due to an increase in the volatility index.
E
Sell
9/7/2022Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 9/7/2022 due to a decline in the volatility index and total return index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 9/7/2022 due to a decline in the volatility index and total return index.
D
Sell
8/22/2022Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 8/22/2022 due to an increase in the total return index, volatility index and growth index. Operating cash flow increased 0.17% from -$28.93M to -$28.88M.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 8/22/2022 due to an increase in the total return index, volatility index and growth index. Operating cash flow increased 0.17% from -$28.93M to -$28.88M.
E
Sell
5/13/2022Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 5/13/2022 due to a noticeable decline in the growth index, solvency index and total return index. The quick ratio declined from 14.58 to 11.66, operating cash flow declined 12.06% from -$25.82M to -$28.93M, and EBIT declined 10.76% from -$34.43M to -$38.13M.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 5/13/2022 due to a noticeable decline in the growth index, solvency index and total return index. The quick ratio declined from 14.58 to 11.66, operating cash flow declined 12.06% from -$25.82M to -$28.93M, and EBIT declined 10.76% from -$34.43M to -$38.13M.
D
Sell
5/5/2022Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 05/05/2022.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 05/05/2022.
E
Sell
4/20/2022Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, volatility index and solvency index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, volatility index and solvency index.
D
Sell
11/9/2021Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 11/9/2021 due to an increase in the growth index and volatility index. Operating cash flow increased 23.94% from -$33.92M to -$25.8M, EBIT increased 15.91% from -$44.54M to -$37.45M, and earnings per share increased from -$0.4523 to -$0.3909.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D- from E+ on 11/9/2021 due to an increase in the growth index and volatility index. Operating cash flow increased 23.94% from -$33.92M to -$25.8M, EBIT increased 15.91% from -$44.54M to -$37.45M, and earnings per share increased from -$0.4523 to -$0.3909.
E
Sell
10/14/2021Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 10/14/2021 due to a decline in the volatility index and total return index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from D- on 10/14/2021 due to a decline in the volatility index and total return index.
D
Sell
8/6/2021Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D- from D on 8/6/2021 due to a significant decline in the total return index, volatility index and growth index. EBIT declined 55.49% from -$28.64M to -$44.54M, earnings per share declined from -$0.2909 to -$0.4523, and operating cash flow declined 52.05% from -$22.31M to -$33.92M.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D- from D on 8/6/2021 due to a significant decline in the total return index, volatility index and growth index. EBIT declined 55.49% from -$28.64M to -$44.54M, earnings per share declined from -$0.2909 to -$0.4523, and operating cash flow declined 52.05% from -$22.31M to -$33.92M.
D
Sell
3/2/2021Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D from D+ on 3/2/2021 due to a decline in the growth index and solvency index. EBIT declined 29.91% from -$28M to -$36.38M, the quick ratio declined from 28.21 to 20.59, and earnings per share declined from -$0.3125 to -$0.3856.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D from D+ on 3/2/2021 due to a decline in the growth index and solvency index. EBIT declined 29.91% from -$28M to -$36.38M, the quick ratio declined from 28.21 to 20.59, and earnings per share declined from -$0.3125 to -$0.3856.
D
Sell
2/4/2021Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D+ from D on 2/4/2021 due to an increase in the solvency index, growth index and total return index. The quick ratio increased from 13.18 to 28.21, earnings per share increased from -$0.364 to -$0.3125, and EBIT increased 5.95% from -$29.78M to -$28M.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D+ from D on 2/4/2021 due to an increase in the solvency index, growth index and total return index. The quick ratio increased from 13.18 to 28.21, earnings per share increased from -$0.364 to -$0.3125, and EBIT increased 5.95% from -$29.78M to -$28M.
D
Sell
9/17/2020Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D from D+ on 9/17/2020 due to a decline in the total return index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D from D+ on 9/17/2020 due to a decline in the total return index.
D
Sell
9/1/2020Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D+ from D on 9/1/2020 due to an increase in the valuation index and volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D+ from D on 9/1/2020 due to an increase in the valuation index and volatility index.
D
Sell
4/2/2020Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D from D+ on 4/2/2020 due to a decline in the valuation index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D from D+ on 4/2/2020 due to a decline in the valuation index.
D
Sell
3/18/2020Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D+ from D on 3/18/2020 due to a major increase in the total return index, solvency index and growth index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D+ from D on 3/18/2020 due to a major increase in the total return index, solvency index and growth index.
D
Sell
10/21/2019Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D from D+ on 10/21/2019 due to a significant decline in the total return index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D from D+ on 10/21/2019 due to a significant decline in the total return index.
D
Sell
8/30/2019Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D+ from D on 8/30/2019 due to a significant increase in the total return index and volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D+ from D on 8/30/2019 due to a significant increase in the total return index and volatility index.
D
Sell
8/2/2018Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D from D+ on 8/2/2018 due to a decline in the total return index and volatility index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D from D+ on 8/2/2018 due to a decline in the total return index and volatility index.
D
Sell
5/11/2018Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D+ from D on 5/11/2018 due to a significant increase in the total return index, volatility index and solvency index. The quick ratio increased from 17.85 to 26.64.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D+ from D on 5/11/2018 due to a significant increase in the total return index, volatility index and solvency index. The quick ratio increased from 17.85 to 26.64.
D
Sell
11/24/2017Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D from D- on 11/24/2017 due to an increase in the total return index, volatility index and valuation index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D from D- on 11/24/2017 due to an increase in the total return index, volatility index and valuation index.
D
Sell
11/9/2017Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D- from D on 11/9/2017 due to a decline in the growth index, efficiency index and solvency index. EBIT declined 31.35% from -$11.09M to -$14.57M, net income declined 20.99% from -$11.43M to -$13.83M, and earnings per share declined from -$0.2658 to -$0.32.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D- from D on 11/9/2017 due to a decline in the growth index, efficiency index and solvency index. EBIT declined 31.35% from -$11.09M to -$14.57M, net income declined 20.99% from -$11.43M to -$13.83M, and earnings per share declined from -$0.2658 to -$0.32.
D
Sell
10/5/2017Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D from D- on 10/5/2017 due to an increase in the solvency index, total return index and volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D from D- on 10/5/2017 due to an increase in the solvency index, total return index and volatility index.
D
Sell
8/25/2017Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D- from D on 8/25/2017 due to a decline in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D- from D on 8/25/2017 due to a decline in the volatility index.
D
Sell
8/10/2017Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D from D- on 8/10/2017 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.382 to -$0.27, EBIT increased 22.42% from -$15.59M to -$12.09M, and operating cash flow increased 3.35% from -$11.82M to -$11.42M.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D from D- on 8/10/2017 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.382 to -$0.27, EBIT increased 22.42% from -$15.59M to -$12.09M, and operating cash flow increased 3.35% from -$11.82M to -$11.42M.
D
Sell
6/21/2016Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D- from D on 6/21/2016 due to a decline in the volatility index.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to D- from D on 6/21/2016 due to a decline in the volatility index.
D
Sell
6/6/2016Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D from D- on 6/6/2016 due to an increase in the growth index and volatility index.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to D from D- on 6/6/2016 due to an increase in the growth index and volatility index.
D
Sell
5/9/2016Downgrade
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to D- from D on 5/9/2016 due to a major decline in the efficiency index, solvency index and growth index. Total revenue declined 72.4% from $960 to $265, EBIT declined 33.62% from -$11.61M to -$15.51M, and operating cash flow declined 33.17% from -$9.13M to -$12.15M.
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to D- from D on 5/9/2016 due to a major decline in the efficiency index, solvency index and growth index. Total revenue declined 72.4% from $960 to $265, EBIT declined 33.62% from -$11.61M to -$15.51M, and operating cash flow declined 33.17% from -$9.13M to -$12.15M.
D
Sell
3/11/2016Downgrade
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to D from D+ on 3/11/2016 due to a major decline in the volatility index, total return index and efficiency index. Total capital declined 3.71% from $262.33M to $252.59M, and net income declined 0.07% from -$14.08M to -$14.09M.
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to D from D+ on 3/11/2016 due to a major decline in the volatility index, total return index and efficiency index. Total capital declined 3.71% from $262.33M to $252.59M, and net income declined 0.07% from -$14.08M to -$14.09M.
D
Sell
3/1/2016Upgraded
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to D+ from D on 3/1/2016 due to an increase in the volatility index, total return index and valuation index.
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to D+ from D on 3/1/2016 due to an increase in the volatility index, total return index and valuation index.
D
Sell
9/1/2015Upgraded
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to D from D- on 9/1/2015 due to a large increase in the efficiency index, growth index and valuation index. Operating cash flow increased 19.48% from -$7.74M to -$9.25M, EBIT increased 3.36% from -$9.56M to -$9.88M, and net income increased 2.7% from -$9.51M to -$9.77M.
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to D from D- on 9/1/2015 due to a large increase in the efficiency index, growth index and valuation index. Operating cash flow increased 19.48% from -$7.74M to -$9.25M, EBIT increased 3.36% from -$9.56M to -$9.88M, and net income increased 2.7% from -$9.51M to -$9.77M.
D
Sell
6/15/2015Downgrade
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to D- from C- on 6/15/2015 due to a decline in the volatility index and valuation index.
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to D- from C- on 6/15/2015 due to a decline in the volatility index and valuation index.
C
Hold
6/10/2015Upgraded
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from D- on 6/10/2015 due to an increase in the volatility index.
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from D- on 6/10/2015 due to an increase in the volatility index.
D
Sell
6/8/2015Downgrade
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to D- from C- on 6/8/2015 due to a decline in the volatility index.
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to D- from C- on 6/8/2015 due to a decline in the volatility index.
C
Hold
6/5/2015Upgraded
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from D- on 6/5/2015 due to a noticeable increase in the volatility index, growth index and valuation index. Operating cash flow increased 53.16% from -$5.06M to -$7.74M.
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from D- on 6/5/2015 due to a noticeable increase in the volatility index, growth index and valuation index. Operating cash flow increased 53.16% from -$5.06M to -$7.74M.
D
Sell
5/5/2015Upgraded
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to D- from E+ on 5/5/2015 due to an increase in the valuation index.
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to D- from E+ on 5/5/2015 due to an increase in the valuation index.
E
Sell
4/20/2015Downgrade
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E+ from C- on 4/20/2015 due to a decline in the volatility index and valuation index.
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E+ from C- on 4/20/2015 due to a decline in the volatility index and valuation index.
C
Hold
4/14/2015Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to C- from E+ on 04/14/2015.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to C- from E+ on 04/14/2015.
E
Sell
4/13/2015Downgrade
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E+ from C- on 4/13/2015 due to a decline in the volatility index.
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E+ from C- on 4/13/2015 due to a decline in the volatility index.
C
Hold
4/10/2015Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to C- from E+ on 04/10/2015.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to C- from E+ on 04/10/2015.
E
Sell
4/9/2015Downgrade
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from C- on 04/09/2015.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E+ from C- on 04/09/2015.
C
Hold
4/8/2015Upgraded
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from E+ on 4/8/2015 due to an increase in the volatility index and valuation index.
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from E+ on 4/8/2015 due to an increase in the volatility index and valuation index.
E
Sell
4/1/2015Downgrade
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E+ from C- on 4/1/2015 due to a decline in the volatility index.
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E+ from C- on 4/1/2015 due to a decline in the volatility index.
C
Hold
3/31/2015Upgraded
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from E+ on 3/31/2015 due to an increase in the volatility index.
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from E+ on 3/31/2015 due to an increase in the volatility index.
E
Sell
3/26/2015Downgrade
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E+ from C- on 3/26/2015 due to a decline in the valuation index.
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E+ from C- on 3/26/2015 due to a decline in the valuation index.
C
Hold
3/12/2015Upgraded
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from E+ on 3/12/2015 due to an increase in the growth index. EBIT increased 31.02% from -$7.94M to -$10.4M, and operating cash flow increased 1.65% from -$4.97M to -$5.06M.
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from E+ on 3/12/2015 due to an increase in the growth index. EBIT increased 31.02% from -$7.94M to -$10.4M, and operating cash flow increased 1.65% from -$4.97M to -$5.06M.
E
Sell
2/13/2015Upgraded
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to E+ from E on 2/13/2015 due to an increase in the volatility index and valuation index.
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to E+ from E on 2/13/2015 due to an increase in the volatility index and valuation index.
E
Sell
1/29/2015Downgrade
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E from C- on 1/29/2015 due to a decline in the total return index.
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E from C- on 1/29/2015 due to a decline in the total return index.
C
Hold
1/26/2015Upgraded
Adverum Biotechnologies, Inc. (ADVM) was upgraded to C- from E on 01/26/2015.
Adverum Biotechnologies, Inc. (ADVM) was upgraded to C- from E on 01/26/2015.
E
Sell
1/23/2015Downgrade
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E from C- on 1/23/2015 due to a decline in the growth index and efficiency index.
Avalanche Biotechnologies, Inc. (AAVL) was downgraded to E from C- on 1/23/2015 due to a decline in the growth index and efficiency index.
C
Hold
12/9/2014Upgraded
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from E on 12/9/2014 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 13.14 to 37.06.
Avalanche Biotechnologies, Inc. (AAVL) was upgraded to C- from E on 12/9/2014 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 13.14 to 37.06.
E
Sell
10/24/2014None
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E from U on 10/24/2014.
Adverum Biotechnologies, Inc. (ADVM) was downgraded to E from U on 10/24/2014.
NASDAQ
04/04/2025 12:51PM Eastern
Quotes delayed
